Clinical Trial Update: 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients [Phase 1]

View source ↗

Summary

Phase 1 study from Boehringer Ingelheim evaluating a 4-week combination of BI 207127 with Pegylated interferon and ribavirin in patients with chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 207127 (BI-207127)
• Pegylated interferon alfa-2a/b (Pegylated interferon alfa-2a/b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2016-04-19